Serina Therapeutics, Inc. (SER) stock
SERNYSEPharmaceutical PreparationsFiscal year ends December 31
$1.41−0.09 (-6.00%)
Close on Nov 12, 2026Market cap $35.81MP/E –Yield –
Serina Therapeutics cash
Cash and short-term investments held at the end of each period.
Serina Therapeutics's cash was $19.40M at Sep 30, 2026. For fiscal 2025 it was $3.06M, down 16.8% from the year before. The highest annual figure on record is $7.62M in fiscal 2023.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.06M | -16.8% |
| FY2024 | Dec 31, 2024 | $3.67M | -51.8% |
| FY2023 | Dec 31, 2023 | $7.62M | +1081.2% |
| FY2022 | Dec 31, 2022 | $645.00K | +10.4% |
| FY2021 | Dec 31, 2021 | $584.00K | +10.8% |
| FY2020 | Dec 31, 2020 | $527.00K | -77.6% |
| FY2019 | Dec 31, 2019 | $2.35M | -64.9% |
| FY2018 | Dec 31, 2018 | $6.71M | -9.1% |
| FY2017 | Dec 31, 2017 | $7.38M | +2747.5% |
| FY2016 | Dec 31, 2016 | $259.00K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $19.40M | +125.1% |
| Q2 FY2026 | Jun 30, 2026 | $23.02M | +281.1% |
| Q1 FY2026 | Mar 31, 2026 | $24.53M | +474.8% |
| Q4 FY2025 | Dec 31, 2025 | $3.06M | -16.8% |
| Q3 FY2025 | Sep 30, 2025 | $8.62M | +170.6% |
| Q2 FY2025 | Jun 30, 2025 | $6.04M | -0.4% |
| Q1 FY2025 | Mar 31, 2025 | $4.27M | -51.0% |
| Q4 FY2024 | Dec 31, 2024 | $3.67M | -51.8% |
| Q3 FY2024 | Sep 30, 2024 | $3.19M | +702.3% |
| Q2 FY2024 | Jun 30, 2024 | $6.06M | +2223.4% |
| Q1 FY2024 | Mar 31, 2024 | $8.71M | +3009.3% |
| Q4 FY2023 | Dec 31, 2023 | $7.62M | +1081.2% |
| Q3 FY2023 | Sep 30, 2023 | $397.00K | -14.8% |
| Q2 FY2023 | Jun 30, 2023 | $261.00K | -62.8% |
| Q1 FY2023 | Mar 31, 2023 | $280.00K | -37.5% |
| Q4 FY2022 | Dec 31, 2022 | $645.00K | +10.4% |
| Q3 FY2022 | Sep 30, 2022 | $466.00K | -36.3% |
| Q2 FY2022 | Jun 30, 2022 | $702.00K | +14.1% |
| Q1 FY2022 | Mar 31, 2022 | $448.00K | -44.6% |
| Q4 FY2021 | Dec 31, 2021 | $584.00K | +10.8% |
| Q3 FY2021 | Sep 30, 2021 | $731.00K | -34.0% |
| Q2 FY2021 | Jun 30, 2021 | $615.00K | -40.5% |
| Q1 FY2021 | Mar 31, 2021 | $809.00K | +72.9% |
| Q4 FY2020 | Dec 31, 2020 | $527.00K | -77.6% |
| Q3 FY2020 | Sep 30, 2020 | $1.11M | -70.6% |
| Q2 FY2020 | Jun 30, 2020 | $1.03M | -82.2% |
| Q1 FY2020 | Mar 31, 2020 | $468.00K | -94.5% |
| Q4 FY2019 | Dec 31, 2019 | $2.35M | -64.9% |
| Q3 FY2019 | Sep 30, 2019 | $3.77M | -55.8% |
| Q2 FY2019 | Jun 30, 2019 | $5.81M | -21.2% |
| Q1 FY2019 | Mar 31, 2019 | $8.59M | +3215.1% |
| Q4 FY2018 | Dec 31, 2018 | $6.71M | – |
| Q1 FY2018 | Mar 31, 2018 | $8.52M | – |
| Q4 FY2017 | Dec 31, 2017 | $7.38M | – |
| Q4 FY2016 | Dec 31, 2016 | $259.00K | – |
See a number that looks wrong?